IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
Filed with ASX · · 2 pages · English
In the deck
Earlier from Immuron
- Immuron Travelan continued strong sales growth
- Immuron Announces Travelan Clinical Trial Update
- NMRC Reports Results for Campylobacter Clinical Study
- Trading Halt
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Later from Immuron
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan highest sales in history
- FY25 global sales exceed projection, up 49% on prior year
- Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
- Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron